- Home
- NIE vs PCRX Comparison
NIE vs PCRX Comparison
Compare NIE & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIE
- PCRX
- Stock Information
- Founded
- NIE 2007
- PCRX 2006
- Country
- NIE United States
- PCRX United States
- Employees
- NIE N/A
- PCRX N/A
- Industry
- NIE Investment Managers
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- NIE Finance
- PCRX Health Care
- Exchange
- NIE Nasdaq
- PCRX Nasdaq
- Market Cap
- NIE 612.1M
- PCRX 604.7M
- IPO Year
- NIE N/A
- PCRX 2011
- Fundamental
- Price
- NIE $23.70
- PCRX $16.52
- Analyst Decision
- NIE
- PCRX Buy
- Analyst Count
- NIE 0
- PCRX 10
- Target Price
- NIE N/A
- PCRX $26.60
- AVG Volume (30 Days)
- NIE 70.5K
- PCRX 545.3K
- Earning Date
- NIE 01-01-0001
- PCRX 11-06-2024
- Dividend Yield
- NIE 9.04%
- PCRX N/A
- EPS Growth
- NIE N/A
- PCRX N/A
- EPS
- NIE N/A
- PCRX N/A
- Revenue
- NIE N/A
- PCRX $694,957,000.00
- Revenue This Year
- NIE N/A
- PCRX $4.59
- Revenue Next Year
- NIE N/A
- PCRX N/A
- P/E Ratio
- NIE N/A
- PCRX N/A
- Revenue Growth
- NIE N/A
- PCRX 4.40
- 52 Week Low
- NIE $18.61
- PCRX $11.16
- 52 Week High
- NIE $22.47
- PCRX $35.95
- Technical
- Relative Strength Index (RSI)
- NIE 58.00
- PCRX 44.28
- Support Level
- NIE $22.89
- PCRX $16.11
- Resistance Level
- NIE $24.21
- PCRX $18.34
- Average True Range (ATR)
- NIE 0.27
- PCRX 0.83
- MACD
- NIE 0.05
- PCRX -0.17
- Stochastic Oscillator
- NIE 61.36
- PCRX 5.33
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments such as aerospace and defense, banks, IT services, software, and others.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.